Pharma

EQS-News: Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca

Retrieved on: 
Wednesday, April 10, 2024
PTHR1, AstraZeneca, Acromegaly, Patient, Sale, Acquisition, Endocrine disease, Cooley LLP, Centerview Partners, Alexion, Pharma, Hypoparathyroidism, Fine chemical

Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca

Key Points: 
  • Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca
    The issuer is solely responsible for the content of this announcement.
  • Alexion, AstraZeneca Rare Disease is looking forward to welcoming talent from Amolyt Pharma.
  • The company led by Thierry Abribat and an exceptional management team has developed innovative therapies for rare endocrine diseases.
  • Centerview Partners LLC and Goldman Sachs Bank Europe SE acted as financial advisors to Amolyt, and Cooley LLP and Jones Day acted as legal counsels for Amolyt and its shareholders.

Nxera Pharma joins the World Orphan Drug Alliance

Retrieved on: 
Monday, April 8, 2024
Disease, Patient, WODA, Pharma, Pharmaceutical industry

Tokyo, Japan and Cambridge, UK, 8 April 2024 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces it has joined the World Orphan Drug Alliance (“WODA” or the “Alliance”), a global alliance of commercial distributors dedicated to providing access to treatments for rare diseases and specialty medicines in complex markets around the world.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 8 April 2024 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces it has joined the World Orphan Drug Alliance (“WODA” or the “Alliance”), a global alliance of commercial distributors dedicated to providing access to treatments for rare diseases and specialty medicines in complex markets around the world.
  • The Alliance consists of 12 member companies and provides access to approximately 200 million rare disease patients across 156 countries.
  • Economic terms would be determined on an individual basis should Nxera decide to in-license any product opportunities from the Alliance.
  • Chris Cargill, President & CEO of Nxera Pharma, commented: “Nxera Pharma is delighted to be a part of WODA’s expansion.

World Orphan Drug Alliance Expands to Japan & South Korea and the African Subcontinent

Retrieved on: 
Monday, April 8, 2024
Disease, Science, Greater, Patient, WODA, Therapy, Ecosystem, CIS, Pharma, CTS, Pharmaceutical industry

Japan, South Korea, and the African subcontinent are now covered by the Alliance.

Key Points: 
  • Japan, South Korea, and the African subcontinent are now covered by the Alliance.
  • TOKYO and ZUG, Switzerland, April 08, 2024 (GLOBE NEWSWIRE) -- The World Orphan Drug Alliance (WODA), a global alliance of commercial distributors dedicated to providing access to treatments for rare diseases and specialty medicines in complex markets around the world, has expanded its reach to include Japan and South Korea, as well as the African subcontinent.
  • “Adding Nxera Pharma, formerly Sosei Heptares, in Japan and South Korea serves to round out our Asian offering.
  • People with rare or orphan diseases in Japan and South Korea deserve better access to effective, life-changing medicines.

ORYZON to Provide Corporate Progress Updates at Several Events in April

Retrieved on: 
Friday, April 5, 2024
Conference, Biotechnology, Genomics, LSX, BST, Pharma, Cryptocurrency

Oryzon has been invited to attend the Investing in Oncology Forum 2024, which will be held at the IVA Konferenscenter in Stockholm (Sweden) on April 10, where the company will provide a corporate update at 14:45 CET and will hold one-on-one meetings with global investors and pharmaceutical companies.

Key Points: 
  • Oryzon has been invited to attend the Investing in Oncology Forum 2024, which will be held at the IVA Konferenscenter in Stockholm (Sweden) on April 10, where the company will provide a corporate update at 14:45 CET and will hold one-on-one meetings with global investors and pharmaceutical companies.
  • The company will hold one-on-one meetings with pharmaceutical companies.
  • Oryzon will take part in the keynote plenary panel entitled “The inflation Reduction Act and its Potential Impact On EU Biotech & Pharma Companies: Demystifying the Future” on April 29 at 16:20 BST.
  • Click on the link for more info about the LSX World Congress 2024

Global Insider Risk Report: Insiders Are Leaving the Door Open to Nation State Abuse

Retrieved on: 
Tuesday, April 9, 2024
Technology, Communications, Utilities, Public Policy, Government, Retail, Energy, Other Professional Services, Finance, Consulting, Banking, Accounting, Professional Services, Security, Other Manufacturing, Other Technology, Supply Chain Management, Software, Networks, Internet, Department Stores, Manufacturing, Data Management, Other Policy Issues, Public Relations, Investor Relations, Theft, I3, HR, Organization, PDF, Inside, Risk management, Risk, ATT&CK, Research, Artificial intelligence, MITRE, AI, Data compression, VPN, Aggregation, IP, Workforce, Public sector, Telecommunications, Pharma, Cisco Webex, Medical device

DTEX Systems , the global leader for insider risk management, today released its 2024 i3 Insider Risk Investigations Report – Foreign Interference: Special Edition .

Key Points: 
  • DTEX Systems , the global leader for insider risk management, today released its 2024 i3 Insider Risk Investigations Report – Foreign Interference: Special Edition .
  • The report also cautions about the rise of the “socially engineered insider”, as foreign state actors increasingly exert their influence and stealth to target, recruit, plant, and exploit insiders.
  • Sixty-eight percent of insider risk events were proactively resolved with follow-up security awareness training and corporate policy changes.
  • The 2024 report is based on more than 1,300 insider investigations conducted by the DTEX Insider Intelligence and Investigations (i3) team throughout 2023 within DTEX’s global customer base.

Calliditas Therapeutics to Attend Conferences in April

Retrieved on: 
Tuesday, April 9, 2024
Congress, Conference, CALT, Future, Sustainability, LSX, Inflation, Pharma, Person, Pharmaceutical industry

STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:

Key Points: 
  • STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:
    Van Lanschot Kempen Life Sciences Conference Amsterdam, Tuesday, April 16, 2024.
  • Renée Aguiar-Lucander, CEO, will be available for one-on-one meetings.
  • World Orphan Drug Congress, Thursday, April 25, 2024, in Boston, MA.
  • Maria Törnsén, President North America, will be moderating a panel, entitled "Partnering in the rare disease space - industry perspective".

Calliditas Therapeutics to Attend Conferences in April

Retrieved on: 
Tuesday, April 9, 2024
Congress, Conference, CALT, Future, Sustainability, LSX, Inflation, Pharma, Person, Pharmaceutical industry

STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:

Key Points: 
  • STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:
    Van Lanschot Kempen Life Sciences Conference Amsterdam, Tuesday, April 16, 2024.
  • Renée Aguiar-Lucander, CEO, will be available for one-on-one meetings.
  • World Orphan Drug Congress, Thursday, April 25, 2024, in Boston, MA.
  • Maria Törnsén, President North America, will be moderating a panel, entitled "Partnering in the rare disease space - industry perspective".

New Survey Results from Cloudbreak Pharma Highlight Disease Burden, Need for Non-surgical Treatment Options for Underdiagnosed and Undertreated Ocular Disease

Retrieved on: 
Friday, April 5, 2024
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Diagnosis, Pterygium, Disease, Eye, Conjunctiva, Safety, Physician, ASCRS, Air conditioning, Conjunctivitis, Tavarua, Tearing, Contact, Dry, Volunteering, Wind, Efficacy, Ophthalmology, Pollen, Chronic, Irritation, Pharmacokinetics, Vision, HCP, Recurrence, Pharma, Food

“Simple tasks like putting in contact lenses, applying makeup and using a computer or phone are made significantly more difficult, if not impossible, for those with pterygium.

Key Points: 
  • “Simple tasks like putting in contact lenses, applying makeup and using a computer or phone are made significantly more difficult, if not impossible, for those with pterygium.
  • As ophthalmologists, we need to listen closely to our patients and coordinate with optometrists to fully understand the impact of pterygium.
  • More information about this trial is available here: Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium .
  • The survey was designed with multiple-choice questions, rating questions and open-ended questions.2

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Tuesday, April 2, 2024
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Shift, Principal, CPI, Drainage, Environment, Refractive surgery, ASCRS, Patient, COE, Acquisition, Faculty, Cataract, MBA, CPC, Society, Safety, Paradigm shift, Pharma, FACS, CPMA, FDA, Annual general meeting, Pharmaceutical industry

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Boston, MA on April 5-8, 2024.

Key Points: 
  • Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Boston, MA on April 5-8, 2024.
  • LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.
  • “The recent acquisition of Visant Medical along with Amring Pharmaceuticals becoming Nordic Pharma, Inc., has increased our internal know-how and assets.
  • This is where science and innovation come together, making it the perfect environment to highlight this novel therapy for dry eye.”

Brenus Pharma Wins the "Biotech" Trophy at the Prestigious Healthtech 2024 Awards Ceremony, Organized by France Biotech

Retrieved on: 
Tuesday, April 2, 2024
Other Health, Research, General Health, Oncology, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, Stem Cells, Health, Partner (business rank), France Biotech, Patient, Cancer, LEEM, Imagination, Creativity, Merck Group, IQVIA, Multimedia, Pharma, Pharmaceutical industry

Brenus Pharma announces its distinction as the "Biotech of the year" received at the annual HealthTech Awards ceremony organized by France Biotech .

Key Points: 
  • Brenus Pharma announces its distinction as the "Biotech of the year" received at the annual HealthTech Awards ceremony organized by France Biotech .
  • The ceremony took place on Monday, March 25th in Paris, gathering key players in the French health innovation ecosystem.
  • (France Biotech Press Release)
    This award testifies to the relevance of Brenus Pharma's mission: to restore the ability of cancer patients to fight resistant tumor cells and avoid relapses like never before.
  • Finally, congratulations to all the winning startups, nominees, and others who thrive and provide daily efforts for the health of patients."